Federica Galvagno

Orbassano, 10043, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Correction: Development and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translation.

Correction: Development and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translation.

Journal: Cancer immunology, immunotherapy : CII

Published: December 23, 2025

Inference of lineage hierarchies, growth, and drug response mechanisms in cancer cell populations without tracking.

Inference of lineage hierarchies, growth, and drug response mechanisms in cancer cell populations without tracking.

Journal: Cell reports methods

Published: November 10, 2025

The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes.

The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytes.

Journal: Cancer immunology, immunotherapy : CII

Published: April 16, 2025

Development and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translation.

Development and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translation.

Journal: Cancer immunology, immunotherapy : CII

Published: March 13, 2025

Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis.

Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis.

Journal: Cancer immunology, immunotherapy : CII

Published: September 06, 2024

Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models.

Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models.

Journal: Molecular oncology

Published: July 27, 2023

PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade.

PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade.

Journal: British journal of cancer

Published: February 24, 2023

Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19.

Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19.

Journal: Biomedicines

Published: July 28, 2022

Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST.

Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST.

Journal: International journal of molecular sciences

Published: July 20, 2022

Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers.

Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers.

Journal: British journal of haematology

Published: July 01, 2022

Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells.

Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 13, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026